您当前的位置: > 详细浏览

Transplantation of ACE2- mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia

摘要: A coronavirus (HCoV-19) has caused the novel coronavirus disease (COVID-19) outbreak in Wuhan, China, Preventing and reversing the cytokine storm may be the key to save the patients with severe COVID-19 pneumonia. Mesenchymal stem cells (MSCs) have been shown to possess a comprehensive powerful immunomodulatory function. This study aims to investigate whether MSC transplantation improve the outcome of 7 enrolled patients with COVID-19 pneumonia in Beijing YouAn Hospital, China from Jan 23, 2020. to Feb 16, 2020. The clinical outcomes, as well as changes of inflammatory and immune function levels and adverse effects of 7 enrolled patients were assessed for 14 days after MSC injection. MSCs could cure or significantly improve the functional outcomes of seven patients with COVID-19 pneumonia in 14 days without observed adverse effect. The pulmonary function and symptoms of all patients with COVID-19 pneumonia were significantly improved in 2 days after MSC transplantation. Among them, two common and one severe patient were recovered and discharged in 10 days after treatment. After treatment, the peripheral lymphocytes were increased and the overactivated cytokine-secreting immune cells CXCR3 CD4 T cells, CXCR3 CD8 T cells, and CXCR3 NK cells were disappeared in 3-6 days. And a group of CD14 CD11c CD11bmid regulatory DC cell population dramatically increased. Meanwhile, the level TNF-α is significantly decreased while IL-10 increased in MSC treatment group compared to the placebo control group. Furthermore, the gene expression profile showed MSCs were ACE2- and TMPRSS2- which indicated MSCs are free from COVID-19 infection. Thus, the intravenous transplantation of MSCs was safe and effective for treatment in patients with COVID-19 pneumonia, especially for the patients in critically severe condition.

  • 来自: 冷子宽
  • 分类: 医学、药学 >> 临床医学
  • 引用: ChinaXiv:202002.00080 (或此版本 ChinaXiv:202002.00080V1)
    (doi:10.12074/202002.00080)
    (CSTR:32003.36.ChinaXiv.202002.00080.V1)
  • 推荐引用方式:Zikuan Leng,Rongjia Zhu,Wei Hou,Yingmei Feng,Yanlei Yang,Qin Han,Guangliang Shan,Fanyan Meng,Dongshu Du,Shihua Wang,Junfen Fan,Wenjing Wang,Luchan Deng,Hongbo Shi,Hongjun Li,Zhongjie Hu,Fengchun Zhang,Jinming Gao,Hongjian Liu,Xiaoxia Li,Yangyang Zhao,Kan Yin,Xijing He,Zhengchao Gao,Yibin Wang,Bo Yang,Ronghua Jin,Ilia Stambler,Lee Wei Lim,Huanxing Su,Alexey Moskalev,Antonio Cano,Sasanka Chakrabarti,Kyung-Jin Min,Georgina Ellison-Hughes,Calogero Caruso,Kunlin Jin,Robert Chunhua Zhao.(2020).Transplantation of ACE2- mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia.CSTR:32003.36.ChinaXiv.202002.00080.V1 (点此复制)

版本历史

[V1] 2020-02-28 05:54:17 ChinaXiv:202002.00080V1 下载全文
点击下载全文
同行评议状态
待评议
许可声明
metrics指标
  • 点击量50067
  • 下载量8993
评论
分享
邀请专家评阅